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We investigated the properties of an  artificial chi- 
meric peptide that contains an Arg-Gly-Asp (RGD)- 
tripeptide,  the  versatile cell  recognition  signal of ex- 
tracellular matrix protein components, coupled to a 
carboxyl-terminal  fragment of the highly  specific 
a-thrombin  hibitor,  hirudin  (residues 53-64): 
WG-SANGDFEEIPEEYL (RGD-hir~din'~-'~). Hi- 
r ~ d i n ~ ~ - ' ~  and RGD-hir~din'~-'~ inhibited  the  fibrino- 
gen  clotting  activity of a-thrombin  and prolonged the 
activated  partial thromboplastin  time of human 
plasma. In  addition, both  peptides  afforded  total  pro- 
tection  to  thrombin  from  trypsinolysis.  Neither 
h i r~din '~- '~  nor R G D - h i r ~ d i n ~ ~ - ' ~  dramatically  inter- 
fered with the thrombin-antithrombin inhibition re- 
action  either  in  the absence or  presence of added  hep- 
arin. a-Thrombin-induced  platelet  aggregation was ef- 
fectively  inhibit d  by  and RGD- 
hir~din'~- '~.  Unlike h i r ~ d i n ~ ~ - ' ~ ,   R G D - h i r ~ d i n ~ ~ - ' ~  in 
solution inhibited integrin-mediated endothelial cell 
and fibroblast  cell  attachment to  polystyrene  wells  in 
the presence of fetal bovine  serum. Collectively, our 
results  demonstrate  that  RGD-hir~din'~-'~  has antico- 
agulant/antiplatelet  aggregation  activity  attributable 
to  its  hirudin sequence and  integrin-directed  cell  at- 
tachment activity due to its RGD site. Our results 
suggest that  this  chimeric motif may serve as a proto- 
type  for  a new class of anticoagulants  where an inte- 
grin-specific  sequence  utargets"  the  peptide  to a cell 
(ultimately  through the  platelet  integrin  trapped 
amid  a  thrombus  with  ensuing  proteinase  inhibition. 
Hirudin is a highly specific a-thrombin  inhibitor isolated 
from the salivary gland of the European bloodsucking leech 
Hirudo medicinalis (1-3). Recent structure-function studies 
have shown that both  amino-  and  carboxyl-terminal domains 
of hirudin bind to thrombin,  and the isolated hirudin  domains 
inhibit thrombin through different mechanisms (4-9). The 
amino-terminal hirudin domain binds to the active site of 
thrombin, whereas the carboxyl-terminal hirudin fragment 
binds to  the fibrinogen recognition site  (adjacent to  the active 
site) (4-9).  Only a small portion of the carboxyl terminus of 
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hirudin is required for anticoagulant activity; the minimal 
peptide length being about 12 amino acid residues to 
Leu64) (4, 5). Hirudin and its fragments have different bio- 
chemical properties as potential therapeutic anticoagulants 
that could favor one over another based on the desired phar- 
macological characteristics. 
Adhesion of blood platelets to vessel  wall components and 
their subsequent activation is a  central hemostatic event. An 
essential component of platelet adhesion and aggregation is 
the cell surface receptor aI& (also known as glycoprotein 
IIb-IIIa), which is  a member of the integrin family (10-14). 
Platelet (YI& is a receptor for four adhesive proteins: fibrin- 
ogen, fibronectin, vitronectin,  and von Willebrand factor (10, 
11, 13). a I Ib& specifically recognizes a conserved tripeptide 
Arg-Gly-Asp (RGD) sequence found in all four proteins  and 
the carboxyl terminus of the y chain of fibrinogen 
(HHLGGAKQAGDV) (10,11,13,15). Additionally, there  are 
many other  integrins found in numerous cell types that spe- 
cifically mediate both cell adhesion with substrates derived 
from extracellular matrix  and body fluids and cell-cell inter- 
actions (10, 16). 
There  are examples of hybrid molecules either that combine 
two functions or that acquire a new function. A bifunctional 
thrombin inhibitor has been prepared by linking (D-Phe)- 
Pro-Arg-Pro- and hirudin carboxyl-terminal fragments (17, 
18). RGD- and HHLGGAKQAGDV-containing sequences 
either coupled to or genetically engineered into a carrier 
protein have integrin-specific cell binding activity similar to 
the  parent adhesive protein (15,19-21). We hypothesized that 
an artificial chimeric peptide could be constructed that incor- 
porated  antithrombin activity and integrin-directed cell at- 
tachment activity. This chimera motif is based on the finding 
that platelet phospholipid microparticles produced following 
platelet activation contain the components for assembly of 
the prothrombinase complex and functional (Y&3 receptors 
(22). Therefore, coupling these sequence types into  a chimera 
might provide a "targeted antithrombin  agent to specifically 
bind cells at a  thrombus for inhibition of thrombin. 
In the present investigation, we synthesized a chimeric 
peptide by adding the RGD tripeptide,  a minimal cell adhesion 
sequence from fibronectin and other adhesive proteins, to a 
segment of the carboxyl terminus of hirudin (termed chimeric 
antithrombin  peptide). We report here that  the chimeric anti- 
thrombin peptide has both antithrombin and cell adhesion 
activities comparable to  its individual constituents. 
EXPERIMENTAL  PROCEDURES 
Materiak-All N-(9-Fluorenyl)methoxycarbonyl-amino acid de- 
rivatives and reagents were obtained from Milligen/Cambridge Re- 
search Biochemicals. Human a-thrombin and antithrombin were 
purified as described (23,24). Heparin was provided by Diosynth; ~ 1 -  
11975 
This is an Open Access article under the CC BY license.
11976 RGD-Hirudin Chimera 
tosylamido-2-phenylethyl chloromethyl ketone-treated trypsin was 
from Cooper Biochemicals. Bovine fibrinogen was from Miles Labo- 
ratories; Chromozyme TH (tosyl-Gly-Pro-Arg-p-nitroanilide) was ob- 
tained from Boehringer Mannheim. 
Peptide Synthesis-Peptides were assembled using a Milligen Pep- 
synthesizer as described previously (25). Purity of the peptides was 
analyzed by reverse-phase HPLC' (24,26),  and if necessary, peptides 
were further purified by HPLC on a  preparative Vydac  Cls column. 
All peptides were analyzed either by amino acid analysis or by primary 
structural analysis on an Applied Biosystems 475A Protein Sequencer 
(Protein Chemistry Laboratory, Department of Chemistry of this 
institution). An excellent correlation between expected and actual 
values/sequences was found for all peptides. Sequences of synthetic 
hirudin"" and R G D - h i r ~ d i n ~ ~ ~ ~  peptides are shown below (pico- 
moles of amino acid yield/cycle are shown in parentheses). 
All other peptides and their sequences using the one-letter abbrevia- 
tion (shown in parentheses) were as follows: RGD-peptide 
(GRGDSAY); RGE-peptide (YARGESA); RGE-hir~din~~"' 
(WGRGESANGDFEEIPEEYL); and HC38-66 (DFHKENTVTND- 
WIPEGEEDDDYLDLEKIY) (25). 
Anticoagulclnt and Antithrombin Assays-All experiments were 
performed in  a buffer that contained 20 mM HEPES, 150 mM NaCI, 
0.1% (w/v) polyethylene glycol ( M ,  = 8000) at  pH 7.4. Fibrinogen 
clotting activity of human a-thrombin was measured in bovine serum 
albumin-coated microtiter plates by incubating 50 p1 of thrombin (10 
nM stock) with 50 p1 of a  synthetic peptide (8-20 p~ stock). After 1 
min, 100 pl of fibrinogen (5 mg/ml stock) was added, briefly agitated, 
and  the absorbance at 405 nm was measured every 5 s for 2 min in a 
VmaX kinetic microplate reader (Molecular Devices). These experi- 
ments were performed in triplicate from three  to five times, aPTT of 
pooled human plasma using Thromboscreen Kontact reagent (Pacific 
Hemostasis) was determined in the presence of synthetic peptides 
with a Fibrometer as described (27). Experiments were performed 
three times and  the results averaged. 
Antithrombin inhibition assay of thrombin in the presence of a 
200-fold molar excess of either hirudin5344 or R G D - h i r ~ d i n ~ ~ - ~ ~  to 
thrombin was performed as described previously (27). Thrombin 
inhibition by antithrombin-heparin  in the presence of synthetic pep- 
tide was performed by incubating 1 nM thrombin with 100 nM 
for 1 min, followed  by 10 nM human antithrombin in  the 
presence of 0.05 to 500 pg/ml heparin. After 20 s, Chromozyme TH 
with polybrene (to neutralize the added heparin) was added, substrate 
hydrolysis was stopped after 60 min by the addition of glacial acetic 
acid, and  the absorbance at 405 nm was determined. Inhibition  rate 
constants were calculated as detailed previously (27).  These experi- 
ments were performed three times. 
Proteolysis of a-Thrombin by Trypsin-Trypsinolysis of a-throm- 
bin was performed with 2.75 p~ thrombin (100 pg in 100 pl) in the 
presence of 125 p~ hirudin"" or R G D - h i r ~ d i n ~ ~ ? ~ ~  in HEPES- 
buffered saline, pH 7.4. After a 5-min incubation at room temperature, 
the reaction was initiated by the addition of 2 pg  of ~l-tosylamido-2- 
phenylethyl chloromethyl ketone-treated  trypsin and stopped after 
120 min by the addition of 1 mM phenylmethylsulfonyl fluoride. The 
extent of proteolysis was assessed by sodium dodecyl sulfate-poly- 
acrylamide gel electrophoresis in 15% slab gels without chemical 
reduction of samples. Silver nitrate was used to  stain  the polypeptides. 
This experiment was performed three times. 
Platelet Aggregation Assay-Platelet aggregation assays were per- 
formed using human platelet-rich plasma (diluted to 300,000 plate- 
lets/pl) by drawing blood (9 parts) into 3.8% (w/v) sodium citrate (1 
part) from a volunteer who had  not had any  aspirin or related products 
for at least 14 days. Platelet aggregation was performed by adding 40 
pl of a  synthetic peptide solution to 450 pl of platelet-rich plasma at 
37 "C. After a 2-min incubation, 10 pl of a-thrombin (0.4 p M  NIH 
The abbreviations used are: HPLC, high performance liquid chro- 
matography; HEPES, 4-(2-hydroxyethyl)-l-piperazineethanesulfonic 
acid  aPTT, activated partial  thromboplastin time; DMEM, Dulbec- 
CO'S modified  Eagle's medium; FBS, fetal bovine serum. 
unit/ml final concentration) was added and  the light transmittance 
(Bio/Data PAP-4 Aggregometer) was recorded. These experiments 
were performed in triplicate four times with four different healthy 
volunteers and  the results averaged. 
Cells and Cell Attachment Assays-Human dermal fibroblasts (sup- 
plied by Dr. R. A. Briggaman, Department of Dermatology of this 
institution) were  grown in DMEM (GIBCO) supplemented with 10% 
FBS, 100 units/ml penicillin and 100 pg/ml streptomycin. The human 
endothelial cell line (EA.hy  926; supplied by Dr. C-J. S Edge11  of this 
institution) was grown as described previously (28). Cell adhesion 
activity of the synthetic peptides was determined as described (29). 
Briefly, -1 X 10' cells/ml of trypsinized cells were  mixed with DMEM 
containing 10% FBS  and 0.5, 0.5, 1.0, 1.5, and 1.5 mg/ml of RGD, 
RGE, h i r u d i ~ P ~ ~ ,   R G D - h i r ~ d i n ~ ~ - ~ ~ ,  or RGE-hir~din~~" peptides, 
respectively (these  concentrations provided approximately equal mo- 
lar amounts of RGD/E). Cells that attached to  the microtiter plate 
wells after incubation for 60 min at  37 "C and  5% CO,  were quantified 
by staining with Crystal Violet, solubilizing the stained cells with 
ethylene glycol monomethyl ether, and  the absorbance at  600  nm  was 
compared with standard curves of serially diluted cells (30). These 
experiments were performed from three  to six times. 
RESULTS 
Anticoagulant and Antithrombin Activities-Coupling the 
cell adhesive RGD sequence (and the inactive RGE con- 
former) to h i r ~ d i n ~ ~ - ~ ~  did not affect the ability of h i r ~ d i n ~ ~ - ~ ~  
to inhibit fibrinogen hydrolysis by thrombin (Fig. 1, top). The 
concentration  required for 50% inhibition (IC5,) for 
h i r ~ d i n ~ ~ " j ~  , R G D - h i r ~ d i n ~ ~ - ~ ~ ,  and RGE-hirudinS3'j4 was -0.6 
p ~ .  There was also a dose-dependent increase in the  aPTT 
of normal pooled human plasma (average clotting  time of 40 
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FIG. 1. Anticoagulant and antithrombotic activities of syn- 
thetic peptides. Top, fibrinogen clotting activity of human a-throm- 
bin was measured as described under "Experimental Procedures": 
sentially the same activity as shown here for h i r ~ d i n ' ~ - ~ ~  and RGD- 
hir~din'"~  (data  not included). A control peptide, HC39-66 (O), did 
not inhibit fibrinogen clotting activity. Bottom, aPTT assays were 
performed using normal human pooled plasma as detailed under 
"Experimental Procedures." The control HC39-66 peptide did not 
prolong the  aPTT (tested at 10 p ~ ) .  
hirudinS3-64 (0) and  RGD-hir~din'~.~' (A). R G E - h i r ~ d i n ~ ~ - ~ '  had es- 
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FIG. 2. Effect of h ir~din~' - '~  on thrombin inhibition by  anti- 
thrombin-heparin. Thrombin inhibition by antithrombin in the 
presence of various amounts of heparin was performed  as  detailed 
under  "Experimental Procedures" either  in  the  absence (0) or in  the 
presence (A) of hirudinSR-". Thrombin  inhibition was determined as 
the  second-order  rate  constant of inhibition (X  10"j M" s-'). 
and  RGE-hir~din'"'~ (Fig. 1, bottom). 
We examined thrombin inhibition by the plasma serpin 
antithrombin in the presence of h i r ~ d i n ~ ~ - ' ~  and RGD- 
hirudin"-G4. Neither h i r~din~" '~  nor RGD-hir~din~"'~  inter- 
fered with the  thrombin-antithrombin inhibition  reaction (in 
the absence of added heparin)  as shown by second-order rate 
constants of 1.37, 1.22, and 1.34 (X lo5 M" min-') in the 
absence of peptide, and in the presence of a ZOO-fold molar 
excess of h i r ~ d i n ' ~ ' ~ ~  or RGD-hir~din"~'~ to thrombin, re- 
spectively. 
We also determined the effect of h i r ~ d i n ~ ~ - ~ ~  on  thrombin 
inhibition by antithrombin-heparin. At a 100-fold molar ex- 
cess of hirudin"-64 to thrombin, there was essentially no 
difference in the  rate of thrombin inhibition by antithrombin 
in  the presence of various amounts of heparin (Fig. 2). 
Trypsin hydrolyzes a-thrombin at  unique sites in the B- 
chain  to form &- and yT-thrombin derivatives. We assessed 
the effect of hirudin53" and  RGD-hir~din'"~~ on  trypsinolysis 
of a-thrombin.  Both and  RGD-hin~din"-'~ af- 
forded essentially total protection to  a-thrombin during  in- 
cubation with trypsin (Fig. 3). Control  experiments verified 
that the hir~din"-~~-containing peptides had no inhibitory 
effect on  trypsin. 
We examined the peptides for dose-dependent  inhibition of 
platelet aggregation in a-thrombin-stimulated  human  plate- 
lets. Platelet aggregation induced by a-thrombin was inhibited 
most effectively by h i ~ d i n " ~ - ~ ~ ,   R G D - h i r ~ d i n ~ " ~ ~ ,  and RGE- 
(IC50 of 7 pM for each  peptide), but less effectively 
by the RGD-peptide (IC50 -100 p ~ ) ,  and with  no effect by 
the RGE-peptide (tested to 300 p ~ ) . '  Complete inhibition of 
a-thrombin-induced  platelet aggregation was observed with 
15 PM h i r ~ d i n ~ " ~ ~ ,   R G D - h i r ~ d i n ~ ~ - ' ~ ,  and  RGE-hir~din '~-~~.  
These data indicate that  the fibrinogen clotting and platelet 
aggregation activities of a-thrombin  (in a purified or plasma- 
based assay system) are inhibited to essentially the same 
extent by and  RGD/E-hir~din'~-'~  and that addi- 
hirudin53-G4 
RGD-containing  peptides  prevent  platelet aggregation by  inhib- 
iting fibrinogen binding to activated  platelets (10-14). Thus,  in  ad- 
dition to  testing  the  hirudin  site of RGD-hir~din":"~'  to block throm- 
bin-mediated platelet aggregation, we also compared the synthetic 
peptides for dose-dependent  inhibition  in  ADP-stimulated  platelets. 
There was a similar  concentration  dependence for the  RGD-peptide 
and RGD-hirudin""j4 to  inhibit  ADP-stimulated  platelet aggregation 
(J. L. Woods and F. C. Church,  unpublished  observation). 
FIG. 3. Effect of hirudins3-" and RGD-hirudin6"'"  on tryp- 
sinolysis of a-thrombin. Trypsinolysis of a-thrombin was per- 
formed  in  the  absence  and  presence of hirudin"'-64 and RGD-hirudin":" 
" as described under  "Experimental Procedures"  with assessment of 
proteolysis by gel electrophoresis. Lanes: a, Bio-Rad low molecular 
weight standards; b, thrombin alone; c, thrombin plus trypsin; d,  
thrombin  plus  trypsin  and hirudin"':"fi4; and e, thrombin  plus  trypsin 
and RGD-hirudin":"". 
TABLE I 
Inhibition of cell adhesion by synthetic  oeotides 
Peptide 
Cell adhesion (absorbance 600 nmY 
Endothelial cells Fibroblasts 
% 
RGD 53 (0.121 k 0.007)  34  (0.097 k 0.003) 
RGD-hir~din"-'~ 
RGE 
45 (0.103 f 0.007) 37  (0.103 f 0.006) 
96 (0.219 k 0.056) 79  (0.223 k 0.017) 
91 (0.207 * 0.020) 81 (0.229 f 0.024) 
RGE-hirudin"" 92 (0.209 f 0.073) 80 (0.225 f 0.010) 
HirudinS3-fi4 
~ 
., Cell adhesion was measured by Crystal Violet staining of cells as 
described under "Experimental Procedures." The data are from a 
representative  experiment  and  they  are  consistent  with  the  trend in 
all  experiments  evaluating  these  peptides  to  inhibit cell adhesion in 
the  presence of FBS. The 100% cell adhesion value was arbitrarily 
assigned to  the lowest dilution of cells (-1 X IO4 cells) in the  standard 
curve which gave absorbances a t  600 nm of 0.228 and 0.262 for 
endothelial cells and  fibroblasts, respectively. 
tion of the  RGD/E sequence to hirudin""-64 is not detrimental 
to its anticoagulant and  antithrombin activities. The  data also 
suggest that hir~din":"'~ and RGD-hirudin"" bind to the 
same site on  thrombin  since  neither influences inhibition by 
the plasma serpin antithrombin  and both  protect  thrombin 
during trypsinolysis. 
Cell Adhesion Activity-We compared each synthetic pep- 
tide  in  solution for its ability to inhibit fibroblast and endo- 
thelial cell attachment in the presence of FBS. Cell surface 
integrins will bind to RGD-containing adhesive proteins pres- 
ent in  serum as  FBS coats the microtiter plate surface. We 
found that  RGD-hir~din"-~~  and  the RGD-peptide were quite 
effective at  preventing cell attachment, whereas hirudin""'", 
the RGE-peptide, and  RGE-hir~din"'-'~ did not  interfere with 
cell adhesion (Table I). Microscopic inspection of fibroblasts 
and endothelial cells verified that hirudin"-", the RGE-pep- 
tide, and  RGE-hir~din"-~~ had no noticeable effect on cell 
attachment. However, RGD-hirudin"-"' and  the RGD-peptide 
did affect adhesion in that  the cells were rounded and not 
attached  to  the surface (shown for fibroblasts  in Fig. 4). These 
data demonstrate that RGD-hir~din"-'~ functions like the 
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F I ~ ; .  4. Effect of synthetic pept ides   on fibroblast adhesion. 
Inhihition o f '  filwoblast cell adhesion in the  presence of' DMRM/FRS 
with  and  without  synthetic  peptides was performed as descrilml  under 
"Experimental Procedures." u, DMEM/FRS alone: h, DMEM/FHS 
and  the  RGD-peptide; c, DMEM/FRS  and hirudin"" "I; and d, 
DMEM/FRS  and  RGD-hirudin" I". 
RGD-peptide in inhibition of cell adhesion, but that the 
We investigated whether RGD-hirudin":"'" could act  as  a 
"bridge" between RGD-specific cell receptors  and  thrombin 
(as  a  replacement for the adhesive proteins  present in FBS). 
We  prepared  thrombin complexes with RGD-hirudin"""'" and 
and  adsorbed  the  thrombin-peptide complexes to 
polystyrene; next, fibroblasts were added in the absence of 
FBS,  and  the  number of fibroblasts  attached  and  spread were 
determined.  Interestingly,  thrombin  alone  or in  complex  with 
the peptides promoted  the  adhesion  and  spreading of fibro- 
blasts to -70% of the adhesion observed with fibronectin 
(data  not included). It  should be noted  that  the  B-chain of 
thrombin  has  an  RGD sequence  which apparently  acts  as  an 
adherent  substrate  (31).  Thus, we were not  able  to  demon- 
strate  the  coordinating  activities of cell adhesion and  throm- 
bin inhibition with our  initial chimeras. This could be due  to 
not only the "active" RGD adhesion sequence  in thrombin for 
fibroblasts (31) or the actual amount of an RGD-peptide 
necessary to  support cell adhesion  (10)  but  also possibly to 
the absence of an  adequate "spacer" separating  the two active 
sites in this  chimera. 
hirudin.-,.l il sequence alone does not affect cell adhesion. 
hirudin.->'l 1 2  
DISCUSSION 
This  study was undertaken  to  characterize  a  chimera  com- 
bining RGD and  hirudin sequences. Our results  with  RGD- 
are in accord with previous observations using 
hirudin carboxyl-terminal fragments in anticoagulant, anti- 
thrombin,  and  platelet aggregation inhibition  assays (4-9,32- 
35). Our data  and  those of others  indicate  that  hirudin  car- 
boxyl-terminal  fragments  bind  to  the fibrinogen  recognition 
site (anion exosite domain) of thrombin which effectively 
blocks both fibrinogen clotting  and  thrombin-stimulated 
platelet aggregation  activities. These  hirudin  fragments  also 
do  not affect thrombin  inhibition by the  serpin  antithrombin 
with or without heparin. Thus, hirudin fragments that are 
targeted  to  the  anion  exosite of thrombin,  not  the  active  site, 
may work independently of antithrombin  to regulate throm- 
bin. Future chimeric antithrombin peptide designs for the 
hirudin site will include variations in the sequence of the 
carboxyl-terminal  fragment (36) and specific chemical modi- 
fication of Tyr".' (either by nitration  (37),  iodination  (37),  or 
hirudin,~>:i-l;.l 
sulfation  (5)) in an  effort  to increase its overall antithrombin/ 
anticoagulant potency. 
Our results demonstrate that RGD-hirudin":""' has the 
same cell-binding activity as the RGD-peptide alone; thus, 
RGD  in  the RGD-hirudin":""" chimera  must  assume  an active 
conformation.  Many  proteins have  been  identified that  con- 
tain the RGD tripeptide sequence, but the presence of an 
RGD sequence  does not necessarily  confer cell adhesion ac- 
tivity (10). There is sufficient evidence to suggest that  both 
RGD  conformation  and  environment  contribute  to  integrin- 
directed cell recognition (10, 13, 20, 29, 38-41). This recog- 
nition specificity (and  affinity) for RGD-containing  peptides/ 
proteins implies that  a  unique sequence can be "engineered" 
to preferentially interact with a particular integrin (for in- 
stance, by stereochemical isomerization,  cyclization, or  a 
unique  next-neighbor sequence). Indeed,  RGD  peptide-albu- 
min conjugates have been shown to recognize specific inte- 
grins (19,  21). 
curl& is the  dominant fibrinogen receptor  in  platelets (10- 
14).  Cross-linking  studies  have shown that RGD binds  pre- 
dominantly  to  the p:( subunit, whereas HHLGGAKQAGDV 
binds  to  the CYIII, subunit.  There  are  other fibrinogen  receptors 
including the a,& integrin found primarily on endothelial 
cells (40) and aM/3. on leukocytes (42). Comparison of the 
binding specificity of all& and a& for  fibrinogen  shows that 
allt,fi:3 preferentially recognizes both  an  RGD-peptide modeled 
HHLGGAKQAGDV  sequences,  whereas exclusively in- 
teracts  with  an  RGD-peptide modeled after  the Aa5i'"5i.' RGD 
sequence  (40). There  are  many  other  integrins  that  interact 
with different protein sites than those just described, for 
instance, leukocyte a& binds  a novel fibrinogen site  (neither 
RGD nor  the carboxyl terminus of the  y-chain)  (42)  and alpI 
in a melanoma cell line recognizes a fibronectin sequence 
consisting of X-Asp-Y  (43).  Therefore,  it would appear  that 
appropriate  peptide sequences can be designed to specifically 
target  the  chimera  to  platelet alll,p:l and  not  other  integrins 
capable of binding fibrinogen or  other  proteins. 
Previous studies have shown that RGD-and HHLGGA- 
KQAGDV-containing  peptides  prevent fibrinogen binding  to 
platelets  and  platelet aggregation and  alter  the  conformation 
of purified platelet allI&, (10-15).? These  peptide sequences 
have been implicated  as  potential  candidates for therapeutic 
antiplatelet  agents (13, 14).  Furthermore, a family of RGD- 
containing proteins from a variety of snake venoms and 
leeches has recently been described as potent antiplatelet 
compounds (44, 45). Future chimeric antithrombin peptide 
designs  for the  integrin-directed  site  (platelet a111,pJ will in- 
corporate unique/specific  RGD  sequences (such  as  that  in  the 
chain or that found in the snake venom 
RGD-protein  family)  and  non-RGD sequences (such  as  that 
in the fibrinogen y-chain""""'" sequence). 
The possibility for an achievable targeted chimeric anti- 
thrombin  peptide is strengthened by Bode et al. (46),  Sandberg 
et al. (47),  and more  recently by the work of Sims et al. (22) 
in their  detection of both  functional  prothrombinase complex 
components  and allt,p:, incorporated  into  platelet plasma 
membrane microparticles.  We ultimately envision a chimeric 
antithrombin  peptide  combining  al,t,~:l-specific  and  thrombin 
anion exosite-directed active sites. This peptide would be 
capable of interacting  with  stimulated  platelets  trapped within 
a  thrombus  and  not only  blocking platelet-fibrinogen  (or  other 
RGD-containing  proteins)  interactions  but also halting 
thrombin-mediated fibrinogen clotting  and  platelet aggrega- 
tion activities. Finally,  the  partnership of distinct/different 
after Aa$I:? $15 RGD  (but not AaRiS-Ri4 RGD)  and  y-chain400~4'1 
fibrinogen Aa!K-$15 
RGD-Hirudin Chimera 11979 
target sites in these chimeras might support cooperative mul- 
tifunctional activities. 
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